Carcinogenesis, Teratogenesis & Mutagenesis ›› 2007, Vol. 19 ›› Issue (2): 149-151.doi: 10.3969/j.issn.1004-616x.2007.02.020

Previous Articles     Next Articles

Study on the Mutagenesis of Rubitecan

MA Guo-jian1, CHEN Sen-qing1, GAO Ling2, ZHANG Qin-fen2, KANG Shou-hai2, XU Rong-hua2, XUE Kai-xian1   

  1. 1.Laboratory of Genetics, Jiangsu Institute for Cancer Research, Nanjing 210009, Jiangsu, China; 2.Laboratory of pharmacology, Jiangsu Institute for Cancer Research, Nanjing 210009, Jiangsu, China
  • Received:2006-06-06 Revised:2006-10-19 Online:2007-03-30 Published:2007-03-30
  • Contact: MA Guo-jian

Abstract: BACKGROUND & AIM: To study the mutagenesis of Rubitecan (9NC). MATERIALS AND METHODS: The micronucleus test in human lymphocytes (in vitro) and in bone marrow PCE of mice (in vivo) were used. Induction of transplantated tumor in mice with 9NC was observed. RESULTS: 9NC had no mutagenicity in human lymphocytes within 0~0.187μg/ml and no mutagenicity to murine bone marrow PCE within 0~0.375 mg/kg body weight (P>0.05), but could inhibit the growth of transplantated tumor Hpes (heptome) and S180 (sarcoma) in mice. Mutagenic effects of 9NC was found with dosages of ≥0.25 μg/ml (in vitro) and ≥0.75 mg/kg body weight (in vivo). CONCLUSION: 9NC demonstrated mutatgenic effects at different dose ranges.

Key words: Rubitecan(9NC), mutagenesis, micronucleus test

CLC Number: